Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor

Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor

SHANGHAI, April 2, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II...

Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting

SHANGHAI, March 26, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of 6 studies as poster presentation at the AACR Annual Meeting to be held...

Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND

Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND

SHANGHAI, July 22, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 7MW3711 for advanced malignant solid tumor was approved by the National...

menu
menu